Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide

BACKGROUND: Tenofovir alafenamide (TAF) is a new formulation of tenofovir disoproxil fumarate (TDF) that was approved in 2015. While clinical trial evidence suggests that TAF has more favorable outcomes related to kidney injury and loss of bone mineral density, TAF also leads to higher lipid levels...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Manag Care Spec Pharm
Main Authors: Hung, Anna, Sinclair, Matthew, Hemmersbach-Miller, Marion, Edmonston, Daniel, Wyatt, Christina
Formato: Artigo
Idioma:Inglês
Publicado em: Academy of Managed Care Pharmacy 2020
Assuntos:
Research Brief
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8098116/
https://ncbi.nlm.nih.gov/pubmed/33251997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2020.26.12.1582
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados